Risk Factor for Rash in Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia
Both multivariate logistic regression analysis and matched pair analysis identified pre-existing leukopenia as a primary risk factor for rash development associated with cytarabine and idarubicin chemotherapy.
Authors
- Hiroyuki Watanabe (ORCID: https://orcid.org/0000-0001-8744-9799)
- Toshikazu Tsuji (ORCID: https://orcid.org/0000-0002-3424-2927)
- HIROKO YONEMITSU
- Takehiro Kawashiri (ORCID: https://orcid.org/0000-0002-7708-2855)
- ERIKA MOCHIZUKI
- Nana Ozawa
- Ichiro Ieiri (ORCID: https://orcid.org/0000-0002-3543-2562)
- Hideki Ochiai (ORCID: https://orcid.org/0000-0001-9303-5250)
- Nobuaki Egashira (ORCID: https://orcid.org/0000-0002-3673-6824)
- Mayako Uchida (ORCID: https://orcid.org/0000-0003-0507-7309)
- Kimitaka Suetsugu
- Shigeru Ishida (ORCID: https://orcid.org/0000-0002-7234-0464)
- Koichi Akashi (ORCID: https://orcid.org/0000-0001-7763-5723)
- K. Kato
- H Nakamura
Institutions
- Setsunan University (JP)
- Kyushu University (JP)
- Wakayama Medical University (JP)
- Kyushu University Hospital (JP)
- Fukuoka Tokushukai Hospital (JP)
- Doshisha Women's College of Liberal Arts (JP)
Publication Details
- Journal
- Cancer Diagnosis & Prognosis
- Published
- 2024-09-01
- DOI
- https://doi.org/10.21873/cdp.10372
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00